Business
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types CD3 bispecific portfolio now includes three candidates ...
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types","length":207,"tagName":"p"},{"type":"text","content":"CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for safety, tumor specificity and clinical impact","length":243,"tagName":"p"},{"type":"text","content":"Mipletamig, continues to outperform benchmarks, trial enrollment continues","length":74,"tagName":"p"},{"type":"text","content":"$15.9 million raised in 2Q25, extending cash runway into late 4Q25","length":66,"tagName":"p"},{"type":"text","content":"SEATTLE, WASHINGTON / ACCESS Newswire / August 11, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology Company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today reported financial results for the quarter ended June 30, 2025, and provided a business update.","length":370,"tagName":"p"},{"type":"text","content":"Second Quarter Highlights","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Pipeline Expansion - Introduced APVO455, a Nectin-4 x CD3 bispecific for solid tumors, expanding the Company's suite of differentiated CRIS-7-derived CD3 - engaging molecules in development, including lead candidate, mipletamig","length":231,"tagName":"p"}]},{"val":[{"type":"text","content":"Mipletamig for acute myeloid leukemia (AML) - Achieved 85% remission* rate (11/13 patients) in frontline AML patients across two trials in combination therapy","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Increased Liquidity - Completed financings that raised a total of $15.9 million, extending cash runway into late 4Q25","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Secured an equity line of credit for up to an additional $25 million in capital","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":585,"olType":false},{"type":"text","content":"*Remission = complete remission (CR) and, complete remission with blood markers that have not yet recovered (CRi)."...